Prothena Corp. PLC | Mutual Funds
Mutual Funds that own Prothena Corp. PLC
CF Woodford Equity Income
7,948,790
19.95%
0
1.55%
07/31/2018
SPDR S&P Biotech ETF
2,910,271
7.31%
7,488
0.76%
09/06/2018
2,648,056
6.65%
-2,808
3.56%
07/31/2018
Vanguard Health Care Fund
2,150,294
5.4%
0
0.07%
06/30/2018
Fidelity Growth Company Fund
1,762,699
4.43%
-220,078
0.06%
07/31/2018
iShares Russell 2000 ETF
840,818
2.11%
-450
0.03%
09/06/2018
Fidelity Select Biotechnology Portfolio
769,935
1.93%
0
0.13%
07/31/2018
T Rowe Price Health Sciences Fund
643,175
1.62%
-669,426
0.08%
06/30/2018
Vanguard Extended Market Index Fund
523,527
1.31%
12,815
0.01%
07/31/2018
Fidelity Series Growth Company Fund
519,177
1.3%
-82,600
0.06%
07/31/2018
| Address |
77 Sir John Rogersons Quay
Dun Laoghaire Dublin 2
Ireland
|
|
Employees
|
- |
| Website |
http://www.prothena.com |
| Updated |
07/08/2019 |
| Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland. |
